Medico Remedies (MEDICO) Stock Overview
Develops, manufactures, and sells pharmaceutical and nutraceutical products in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MEDICO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Medico Remedies Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹38.71 |
| 52 Week High | ₹62.48 |
| 52 Week Low | ₹30.22 |
| Beta | 0.40 |
| 1 Month Change | -3.63% |
| 3 Month Change | -18.32% |
| 1 Year Change | -34.11% |
| 3 Year Change | -52.18% |
| 5 Year Change | n/a |
| Change since IPO | 59.96% |
Recent News & Updates
Earnings Not Telling The Story For Medico Remedies Limited (NSE:MEDICO)
Sep 23
Medico Remedies Limited's (NSE:MEDICO) CEO Looks Like They Deserve Their Pay Packet
Sep 02Recent updates
Earnings Not Telling The Story For Medico Remedies Limited (NSE:MEDICO)
Sep 23Medico Remedies Limited's (NSE:MEDICO) CEO Looks Like They Deserve Their Pay Packet
Sep 02Here's Why Medico Remedies (NSE:MEDICO) Can Manage Its Debt Responsibly
Jun 28If EPS Growth Is Important To You, Medico Remedies (NSE:MEDICO) Presents An Opportunity
Mar 31Medico Remedies Limited (NSE:MEDICO) Shares Slammed 31% But Getting In Cheap Might Be Difficult Regardless
Feb 28Investors Appear Satisfied With Medico Remedies Limited's (NSE:MEDICO) Prospects As Shares Rocket 27%
Jan 11Investors Appear Satisfied With Medico Remedies Limited's (NSE:MEDICO) Prospects As Shares Rocket 27%
Nov 12Medico Remedies Limited's (NSE:MEDICO) P/E Is Still On The Mark Following 25% Share Price Bounce
Sep 21Medico Remedies Limited (NSE:MEDICO) Shares Slammed 33% But Getting In Cheap Might Be Difficult Regardless
Mar 22Here's Why We Think Medico Remedies (NSE:MEDICO) Is Well Worth Watching
Jun 22What You Can Learn From Medico Remedies Limited's (NSE:MEDICO) P/E After Its 27% Share Price Crash
Jun 26Estimating The Fair Value Of Medico Remedies Limited (NSE:MEDICO)
Jun 03Shareholder Returns
| MEDICO | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 2.6% | 2.7% | 6.9% |
| 1Y | -34.1% | 5.1% | 7.0% |
Return vs Industry: MEDICO underperformed the Indian Pharmaceuticals industry which returned 5.1% over the past year.
Return vs Market: MEDICO underperformed the Indian Market which returned 7% over the past year.
Price Volatility
| MEDICO volatility | |
|---|---|
| MEDICO Average Weekly Movement | 9.0% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in IN Market | 10.3% |
| 10% least volatile stocks in IN Market | 4.7% |
Stable Share Price: MEDICO's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: MEDICO's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 213 | Harshit Mehta | medicoremedies.com |
Medico Remedies Limited develops, manufactures, and sells pharmaceutical and nutraceutical products in India. The company offers antibiotics and anti-infectives; beta-lactams-penicillins and cephalosporins; antifungals; vitamins and supplements; cardiovascular products; antipyretic, analgesic, and NSAIDs medicines; antacid and anti-ulcer drugs; antidepressants, antipsychotics, and anti-epileptics; antimalarials; dry syrups; ointments and creams; anti-diabetics; syrups; and miscellaneous products, as well as diuretics, antireterovirals, and steroidal preparations. It also exports its products.
Medico Remedies Limited Fundamentals Summary
| MEDICO fundamental statistics | |
|---|---|
| Market cap | ₹3.17b |
| Earnings (TTM) | ₹115.99m |
| Revenue (TTM) | ₹1.91b |
Is MEDICO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEDICO income statement (TTM) | |
|---|---|
| Revenue | ₹1.91b |
| Cost of Revenue | ₹1.41b |
| Gross Profit | ₹497.07m |
| Other Expenses | ₹381.08m |
| Earnings | ₹115.99m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 30, 2026
| Earnings per share (EPS) | 1.40 |
| Gross Margin | 26.04% |
| Net Profit Margin | 6.08% |
| Debt/Equity Ratio | 18.7% |
How did MEDICO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/13 13:28 |
| End of Day Share Price | 2026/04/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medico Remedies Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.